CoChat

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Abstract

Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd4309

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 74 references

Research works printed but not linked: 3

  1. Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
  2. Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
  3. Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).

Cited by

Items 301–400 of 1,000

Metadata

Authors
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
Affiliations
AstraZeneca (United Kingdom) (GB)
Corresponding author
Pangalos, Menelas N.
Venue
Nature Reviews Drug Discovery
Published
2014-05-16
Volume
13
Issue
6
Pages
419-431
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1967105697
Cited by
1,344
References
75
Citations by year
2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
FWCI
33.03
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords
AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
MeSH terms
Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.